DaVita Analyst Ratings
Truist Financial Maintains DaVita(DVA.US) With Hold Rating, Raises Target Price to $175
DaVita Analyst Ratings
Truist Financial Maintains DaVita(DVA.US) With Hold Rating, Announces Target Price $165
Analysts Conflicted on These Healthcare Names: Autolus Therapeutics (AUTL), DaVita (DVA) and Bruker (BRKR)
Key Takeaways From DaVita Analyst Ratings
DaVita Price Target Raised to $175.00/Share From $169.00 by UBS
DaVita Analyst Ratings
B of A Securities Maintains Underperform on DaVita, Raises Price Target to $145
Bank of America Securities Sticks to Its Sell Rating for DaVita (DVA)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Organon (OGN), Stevanato Group (STVN) and DaVita (DVA)
Barclays Maintains DaVita(DVA.US) With Hold Rating, Maintains Target Price $150
Barclays Keeps Their Hold Rating on DaVita (DVA)
TD Cowen Maintains DaVita(DVA.US) With Hold Rating, Maintains Target Price $150
DaVita (DVA) Gets a Hold From TD Cowen
DaVita Analyst Ratings
TD Cowen Maintains Hold on DaVita, Raises Price Target to $150
TD Cowen Initiates DaVita(DVA.US) With Hold Rating, Announces Target Price $150
Balanced Outlook: Hold Rating on DaVita Amid Valuation and Regulatory Uncertainties
TD Cowen Reaffirms Their Hold Rating on DaVita (DVA)